Exhibit 99.1

 

China Jo-Jo Drugstores Reports Third Quarter 2020 Financial Results

 

HANGZHOU, China, February 14, 2020 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (“Jo-Jo Drugstores” or the “Company”), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China, today announced its financial results for the third fiscal quarter ended December 31, 2019.

 

Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, “We delivered outstanding financial results for the third quarter of 2020, with revenue recording $33.36 million, up 7.9% compared to the same period of last year. Benefiting from the growth in retail drugstores and online pharmacy businesses as well as our strong competitive position in the industry, all of our core businesses performed in line with our expectation. Looking forward, amidst the outbreak of 2019 Novel Coronavirus, we are striving to optimize our inventory and operational execution with effective distribution channels to meet the strong domestic demand of pharmaceutical and other healthcare products as well as healthcare services. We are confident that our professional team is able to deliver compelling value to our customers and the communities we serve. We will continue to focus on successful execution of our long-term growth strategies to unleash the full potential of our consumer-centric healthcare business model and create value for all shareholders.”  

 

Third Quarter of Fiscal 2020 Financial Highlights

 

   For the Three Months Ended December 31, 
($ millions, except per share data)  2019   2018   % Change 
Revenue   33.36    30.92    7.9%
Retail drugstores   21.58    20.87    3.4%
Online pharmacy   3.96    2.49    59.0%
Wholesale   7.82    7.56    3.5%
Gross profit   7.28    7.14    2.1%
Gross margin   21.8%   23.1%   -1.3pp*
Income (Loss) from operations   0.55    (2.13)   NM 
Net income (loss)   0.46    (2.21)   NM 
Earnings (loss) per share   0.02    (0.06)   NM 

 

*Notes: pp represents percentage points

 

  Revenue increased by 7.9% to $33.36 million for the three months ended December 31, 2019 from $30.92 million for the same period of last year.

 

  Gross profit increased by 2.1% to $7.28 million for the three months ended December 31, 2019 from $7.14 million for the same period of last year.

 

 

 

 

  Gross margin decreased by 1.3 percentage points to 21.8% from 23.1% for the same period of last year.

 

  Net income was $0.46 million, or $0.02 per basic and diluted share, for the three months ended December 31, 2019, compared to net loss of $2.21 million, or $0.06 per basic and diluted share, for the same period of last year.

 

Third Quarter of Fiscal 2020 Financial Results

 

Revenue

 

Revenue for the three months ended December 31, 2019 increased by $2.45 million, or 7.9%, to $33.36 million from $30.92 million for the same period of last year. The increase in revenue was primarily due to the growth in retail drugstores and online pharmacy business.

 

   For the Three Months Ended December 31, 
   2019   2018 
($ millions)  Revenue   Cost of Goods   Gross Margin   Revenue   Cost of Goods   Gross Margin 
Retail drugstores   21.58    15.39    28.7%   20.87    14.90    28.6%
Online pharmacy   3.96    3.64    8.2%   2.49    2.23    10.4%
Wholesale   7.82    7.05    9.9%   7.56    6.65    12.1%
Total   33.36    26.08    21.8%   30.92    23.78    23.1%

 

Revenue from the retail drugstores business increased by $0.71 million, or 3.4%, to $21.58 million for the three months ended December 31, 2019 from $20.87 million for the same period of last year. The increase was primarily attributable to the consumer-facing benefits we provided, such as on-site medical care, chronic disease management services, incremental “Direct-to-Patient” (“DTP”) business caused by continuous hospital medical reform, and maturing of stores opened a year ago.

 

2

 

 

Revenue from the online pharmacy business increased by $1.47 million, or 59.0%, to $3.96 million for the three months ended December 31, 2019 from $2.49 million for the same period of last year. The increase was primarily caused by an increase in sales via e-commerce platforms such as Tmall, offset slightly by the decline in sales via the Company’s official site. Popular products at reasonable prices are key to success in online business. In order to promote the Company’s sales, the Company focused on the selection of medical equipment suitable to local customers. Additionally, as more and more customers switch to online OTC drug shopping, the Company’s OTC drug sales grew too.

 

Revenue from the wholesale business increased by $0.26 million, or 3.5%, to $7.82 million for the three months ended December 31, 2019 from $7.56 million for the same period of last year. The increase was primarily a result of the Company's ability to resell certain products, which the Company sold in large quantities at its retail stores, to other vendors at competitive prices.

 

Gross profit and gross margin

 

Total cost of goods sold increased by $2.30 million, or 9.7%, to $26.08 million for the three months ended December 31, 2019 from $23.78 million for the same period of last year. Gross profit increased by $0.14 million, or 2.1%, to $7.28 million for three months ended December 31, 2019 from $7.14 million for the same period of last year. Overall gross margin decreased by 1.3 percentage points to 21.8% for the three months ended December 31, 2019, from 23.1% for the same period of last year.

 

Gross margins for retail drugstores, online pharmacy and wholesale were 28.7%, 8.2%, and 9.9%, respectively, for the three months ended December 31, 2019, compared to the corresponding gross margins of 28.6%, 10.4%, and 12.1% for the same period of last year.

 

Income (Loss) from operations

 

Selling and marketing expenses decreased by $1.01 million, or 15.1%, to $5.68 million for the three months ended December 31, 2019 from $6.69 million for the same period of last year. The decrease in selling and marketing expenses was primarily because the Company has outsourced logistic service to Astro Boy Cloud Pan (Hangzhou) Storage and Logistic Co. Ltd (“Astro Boy Logistic”) since April 2019.

 

3

 

 

General and administrative expenses decreased by $1.52 million, or 59.0%, to $1.05 million for the three months ended December 31, 2019 from $2.57 million for the same period of last year. As the medical reform has been moving along in China, the central government of China promulgated a series of policies to significantly push down the prices of certain drugs covered by the National Health Insurance. Local government even deferred payments to certain clinics and drugstores on the drugs which the local government believes were sold above the government’s designated price range. The price restriction and potential payment deferral may cut the profit and affect the Company’s operating cash flow. To be safe, in the three months ended December 31, 2019, the Company actively negotiated with certain customers and made efforts to collect certain aged accounts receivable. As a result, the Company reversed bad debt allowance of $0.79 million. In comparison, the Company recorded additional bad debts allowance of $0.37 million in the three months ended December 31, 2018.

 

Income from operations was $0.55 million for the three months ended December 31, 2019, compared to loss from operations of $2.13 million for the same period of last year. Operating margin was 1.7% for the three months ended December 31, 2019, compared to operating loss of 6.9% for the same period of last year.

 

Net income (loss)

 

Net income was $0.46 million, or $0.02 per basic and diluted share for the three months ended December 31, 2019, compared to net loss of $2.21 million, or $0.06 per basic and diluted share for the same period of last year.

 

4

 

 

Nine months ended December 31, 2019 Financial Highlights

 

   For the Nine Months Ended December 31, 
($ millions, except per share data)  2019   2018   % Change 
Revenue   87.00    81.10    7.3%
Retail drugstores   56.31    54.97    2.4%
Online pharmacy   8.76    6.64    32.0%
Wholesale   21.93    19.49    12.5%
Gross profit   20.04    18.55    8.0%
Gross margin   23.0%   22.9%   0.1pp*
Income (Loss) from operations   (3.82)   (4.33)   11.8%
Net income (loss)   (3.27)   (4.51)   27.5%
Earnings (loss) per share   (0.09)   (0.14)   35.7%

 

*Notes: pp represents percentage points

 

  Revenue increased by 7.3% to $87.00 million for the nine months ended December 31, 2019 from $81.10 million for the same period of last year.

 

  Gross profit increased by 8.0% to $20.04 million for the nine months ended December 31, 2019 from $18.55 million for the same period of last year.

 

  Gross margin increased by 0.1 percentage points to 23.0% from 22.9% for the same period of last year.

 

  Net loss was $3.27 million, or $0.09 per basic and diluted share, for the nine months ended December 31, 2019, compared to $4.51 million, or $0.14 per basic and diluted share, for the same period of last year.

 

Nine months ended December 31, 2019 Financial Results

 

Revenue

 

Revenue for the nine months ended December 31, 2019 increased by $5.90 million, or 7.3%, to $87.00 million from $81.10 million for the same period of last year. The increase in revenue was primarily due to the increase in wholesale and online pharmacy business.

 

   For the Nine Months Ended December 31, 
   2019   2018 
($ millions)  Revenue   Cost of Goods   Gross Margin   Revenue   Cost of Goods   Gross Margin 
Retail drugstores   56.31    39.54    29.8%   54.97    39.35    28.4%
Online pharmacy   8.76    7.77    11.3%   6.64    5.88    11.4%
Wholesale   21.93    19.65    10.4%   19.49    17.32    11.1%
Total   87.00    66.96    23.0%   81.10    62.55    22.9%

 

5

 

 

Revenue from the retail drugstores business increased by $1.34 million, or 2.4%, to $56.31 million for the nine months ended December 31, 2019 from $54.97 million for the same period of last year. The increase was primarily attributable to the consumer-facing benefits we provided, such as onsite medical care, chronic disease management services, incremental DTP business caused by continuous hospital medical reform, and maturing of stores opened a year ago.

 

Revenue from the online pharmacy business increased by $2.12 million, or 32.0%, to $8.76 million for the nine months ended December 31, 2019 from $6.64 million for the same period of last year. The increase was primarily caused by an increase in sales via e-commerce platforms such as Tmall, offset slightly by the decline in sales via the Company’s official site.

 

Revenue from the wholesale business increased by $2.44 million, or 12.5%, to $21.93 million for the nine months ended December 31, 2019 from $19.49 million for the same period of last year. The increase was primarily a result of the Company's ability to resell certain products, which the Company sold in large quantities at its retail stores, to other vendors at competitive prices.

 

Gross profit and gross margin

 

Total cost of goods sold increased by $4.41 million, or 7.1%, to $66.96 million for the nine months ended December 31, 2019 from $62.55 million for the same period of last year. Gross profit increased by $1.49 million, or 8.0%, to $20.04 million for the nine months ended December 31, 2019 from $18.55 million for the same period of last year. Overall gross margin increased by 0.1 percentage points to 23.0% for the nine months ended December 31, 2019, from 22.9% for the same period of last year.

 

Gross margins for retail drugstores, online pharmacy and wholesale were 29.8%, 11.3%, and 10.4%, respectively, for the nine months ended December 31, 2019, compared to the corresponding gross margins of 28.4%, 11.4%, and 11.1% for the same period of last year.

 

Income (Loss) from operations

 

Selling and marketing expenses increased by $1.59 million, or 9.6%, to $18.13 million for the nine months ended December 31, 2019 from $16.54 million for the same period of last year. The increase in selling and marketing expenses was primarily due to increases in labor related to the Company’s store expansions and rising local cost of living.

 

6

 

 

General and administrative expenses decreased by $0.61 million, or 9.7%, to $5.73 million for the nine months ended December 31, 2019 from $6.34 million for the same period of last year. In the nine months ended December 31, 2019, the Company reversed bad debt allowance of $0.2 million. In comparison, the Company recorded additional bad debts allowance of $1.27 million for the nine months ended December 31, 2018. 

 

Loss from operations was $3.82 million for the nine months ended December 31, 2019, compared to $4.33 million for the same period of last year. Operating loss was 4.4% for the nine months ended December 31, 2019, compared to 5.3% for the same period of last year.

 

Net income (loss)

 

Net loss was $3.27 million, or $0.09 per basic and diluted share for the nine months ended December 31, 2019, compared to net loss of $4.51 million, or $0.14 per basic and diluted share for the same period of last year.

 

Financial Condition

 

As of December 31, 2019, the Company had cash of $11.86 million, compared to $9.32 million as of March 31, 2019. Net cash used in operating activities was $11.27 million for the nine months ended December 31, 2019, compared to $10.32 million for the same period of last year. Net cash used in investing activities was $1.71 million for the nine months ended December 31, 2019, compared to $6.85 million for the same period of last year. Net cash provided by financing activities was $12.70 million for the nine months ended December 31, 2019, compared to $7.98 million for the same period of last year.

 

About China Jo-Jo Drugstores, Inc.

 

China Jo-Jo Drugstores, Inc. (“Jo-Jo Drugstores” or the “Company”), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. In addition, Jo-Jo Drugstores cultivates herbs used for traditional Chinese medicine. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website.

 

7

 

 

Forward-Looking Statements

 

This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission.

 

For more information, please contact:

 

Company Contact: 

 

Frank Zhao
Chief Financial Officer
+86-571-88077108
frank.zhao@jojodrugstores.com

 

Steve Liu
Investor Relations Director
steve.liu@jojodrugstores.com

 

Investor Relations Contact:

 

Tina Xiao
Ascent Investor Relations LLC
+1-917-609-0333
tina.xiao@ascent-ir.com

 

8

 

 

CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES 

CONDENSED CONSOLIDATED BALANCE SHEETS 

(UNAUDITED)

   December 31,   March 31, 
   2019   2019 
ASSETS        
CURRENT ASSETS        
Cash  $11,858,985   $9,322,463 
Restricted cash   12,035,385    15,422,739 
Financial assets available for sale   159,946    180,928 
Notes receivable   48,768    177,278 
Trade accounts receivable   11,465,402    8,692,514 
Inventories   10,962,677    13,955,202 
Other receivables, net   5,862,408    4,438,230 
Advances to suppliers   1,393,247    1,950,252 
Other current assets   1,505,995    2,063,375 
Total current assets   55,292,813    56,202,981 
           
PROPERTY AND EQUIPMENT, net   8,097,428    8,727,358 
           
OTHER ASSETS          
Long-term investment   9,846    24,243 
Farmland assets   747,782    825,259 
Long term deposits   1,481,929    2,157,275 
Other noncurrent assets   1,134,643    1,196,197 
Operating lease right-of-use assets   15,318,428    - 
Intangible assets, net   3,715,629    3,597,323 
Total other assets   22,408,257    7,800,297 
           
Total assets  $85,798,498   $72,730,636 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable, trade   15,870,874    23,106,230 
Notes payable   21,758,227    25,951,673 
Other payables   2,590,186    3,197,221 
Other payables - related parties   375,068    795,179 
Customer deposits   1,201,464    771,942 
Taxes payable   433,026    125,859 
Accrued liabilities   793,942    1,264,182 
Long-term loan - current portion   2,302,924    - 
Current portion of operating lease liabilities   409,756    - 
Total current liabilities   45,735,467    55,212,286 
           
Long-term loan   4,773,114    - 
Long term operating lease  liabilities   12,670,694    - 
Purchase option and warrants liability   120,000    465,248 
Financial liability   71,757    81,935 
Total liabilities   63,371,032    55,759,469 
           
COMMITMENTS AND CONTINGENCIES          
           
STOCKHOLDERS’ EQUITY          
Common stock; $0.001 par value; 250,000,000 shares authorized; 32,936,786 and 28,936,778 shares issued and outstanding as of December 31, 2019 and March 31, 2019   32,937    28,937 
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of December 31, 2019 and March 31, 2019   -    - 
Additional paid-in capital   54,209,301    44,905,664 
Statutory reserves   1,309,109    1,309,109 
Accumulated deficit   (33,415,600)   (30,587,468)
Accumulated other comprehensive income   1,926,259    2,508,964 
Total stockholders’ equity   24,062,006    18,165,206 
Noncontrolling interests   (1,634,540)   (1,194,039)
Total equity   22,427,466    16,971,167 
Total liabilities and stockholders’ equity  $85,798,498   $72,730,636 

9

 

 

CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) 

(UNAUDITED)

 

   For the three months ended
December 31,
   For the nine months ended
December 31,
 
   2019   2018   2019   2018 
                 
REVENUES, NET  $33,363,282   $30,916,549   $86,997,845   $81,098,161 
                     
COST OF GOODS SOLD   26,079,910    23,780,763    66,959,671    62,548,471 
                     
GROSS PROFIT   7,283,372    7,135,786    20,038,174    18,549,690 
                     
SELLING EXPENSES   5,676,400    6,688,577    18,130,799    16,539,078 
GENERAL AND ADMINISTRATIVE EXPENSES   1,054,060    2,572,862    5,729,607    6,342,874 
TOTAL OPERATING EXPENSES   6,730,460    9,261,439    23,860,406    22,881,952 
                     
INCOME (LOSS) FROM OPERATIONS   552,912    (2,125,653)   (3,822,232)   (4,332,262)
                     
INTEREST INCOME   272,773    18,964    661,160    92,196 
OTHER INCOME (LOSS), NET   (302,408)   32,795    (437,118)   12,436 
                     
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES   (65,172)   (85,115)   345,248    (173,955)
                     
INCOME (LOSS) BEFORE INCOME TAXES   458,105    (2,159,009)   (3,252,942)   (4,401,585)
                     
PROVISION FOR INCOME TAXES   2,184    47,958    16,274    104,712 
                     
NET INCOME (LOSS)   455,921    (2,206,967)   (3,269,216)   (4,506,297)
                     
ADD: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST   75,861    528,736    441,084    594,796 
                     
NET INCOME (LOSS) ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.   531,782    (1,678,231)   (2,828,132)   (3,911,501)
                     
Foreign currency translation adjustments   358,868    (130,619)   (582,705)   (957,646)
                     
COMPREHENSIVE INCOME (LOSS)  $814,789   $(2,337,586)  $(3,851,921)  $(5,463,943)
                     
WEIGHTED AVERAGE NUMBER OF SHARES:                    
Basic   32,936,786    28,936,778    32,776,786    28,936,778 
Diluted   32,936,786    28,936,778    32,776,786    28,936,778 
                     
EARNINGS PER SHARES:                    
Basic  $0.02   $(0.06)  $(0.09)  $(0.14)
Diluted  $0.02   $(0.06)  $(0.09)  $(0.14)

 

10

 

 

CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   For the
nine months ended
December 31,
 
   2019   2018 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss  $(3,269,216)  $(4,506,297)
Adjustments to reconcile net income to net cash provided by operating activities:          
Bad debt direct write-off and provision   (29,038)   1,266,994 
Depreciation and amortization   1,572,925    937,268 
Stock based compensation   34,560    121,547 
Change in fair value of purchase option derivative liability   (345,248)   173,955 
Accounts receivable, trade   (2,581,208)   (4,061,698)
Notes receivable   122,175    (43,024)
Inventories and biological assets   2,484,432    1,828,232 
Other receivables   (1,353,544)   (681,667)
Advances to suppliers   (222,928)   (911,061)
Other current assets   (1,758,533)   476,909 
Long term deposit   597,084    18,548 
Other noncurrent assets   17,744    23,206 
Accounts payable, trade   (6,397,104)   (3,945,980)
Other payables and accrued liabilities   (917,398)   815,725 
Customer deposits   458,415    (2,258,202)
Taxes payable   312,192    422,665 
Net cash used in operating activities   (11,274,690)   (10,322,880)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Disposal of financial assets available for sale   14,370    87,471 
Purchase of financial assets available for sale   -    (104,577)
Acquisition of equipment   (561,677)   (5,368,240)
Increase in intangible assets   (461,013)   (29,879)
Investment in a joint venture   -    - 
Additions to leasehold improvements   (705,856)   (1,432,060)
Net cash used in investing activities   (1,714,176)   (6,847,285)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from third parties loan   7,085,406    - 
Proceeds from notes payable   36,537,832    32,903,549 
Repayment of notes payable   (39,784,592)   (24,930,903)
Increase in financial liability   (7,185)   82,167 
Proceeds from equity financing   9,273,077    7,544 
Repayment of other payables-related parties   (406,506)   (82,866)
Net cash provided by financing activities   12,698,032    7,979,491 
           
EFFECT OF EXCHANGE RATE ON CASH   (559,998)   (1,653,988)
           
DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH   (850,832)   (10,844,662)
           
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period   24,745,202    31,452,191 
           
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of period  $23,894,370   $20,607,529 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid for income taxes  $17,215   $56,539 

 

 

11

 

 

View differences made from one to another to evaluate China Jojo Drugstores, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by China Jojo Drugstores, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Log in with your credentials

or    

Forgot your details?

Create Account